The Effect of Dosing Interval on the Efficacy of Misoprostol in the Prevention of Aspirin-Induced Gastric Injury

Journal of Veterinary Internal Medicine

Volumn 17, Issue 3, 2003, Pages 282-290

  Ward, Deborah M ^a   Leib, Michael S ^a   Johnston, Spencer A ^a   Marini, Michele ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

Gastric ulceration; Nonsteroidal anti inflammatory drugs; Prostaglandins; Salicylates

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; MISOPROSTOL; PLACEBO; ANTIULCER AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG DISEASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; EVALUATION; GASTRODUODENAL ULCER; GASTROSCOPY; HEMORRHAGIC GASTRITIS; INTERMETHOD COMPARISON; NONHUMAN; RANDOMIZATION; SCORING SYSTEM; STOMACH MUCOSA LESION; STOMACH PROTECTION; ULCER PERFORATION; ANIMAL; ANIMAL DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOG; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; PATHOLOGY; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; STOMACH;

ANIMALIA; CANIS FAMILIARIS;

ANIMALS; ANTI-ULCER AGENTS; ASPIRIN; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MISOPROSTOL; PEPTIC ULCER; STOMACH;

EID: 0038143314     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2003)017<0282:TEODIO>2.3.CO;2     Document Type: Article

References (74)

1. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-235.
2. Griffin M. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104:23S-29S.
3. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory Drugs. N Engl J Med 1999;340:1888-1899.
4. Vane J, Botting R. Mechanism of action of non-steroidal antiinflammatory drugs. Am J Med 1998;104:2S-8S.
5. Xie W, Robertson D, Simmons D. Mitogen-inducible prostaglandin G/H synthase; a new target for non-steroidal antiinflammatory drugs. Drug Dev Res 1992;25:249-265.
6. Garcia-Rodriguez L, Jick H. Risk of upper intestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-772.
7. Daehler M. Transmural pyloric perforation associated with naproxen administration in a dog. J Am Vet Med Assoc 1986;189:694-695.
8. Roudebush P, Morse G. Naproxen toxicosis in a dog. J Am Vet Med Assoc 1981;179:805-806.
9. Shaw N, Burrows C, King R. Massive gastric hemorrhage induced by buffered aspirin in a Greyhound. J Am Anim Hosp Assoc 1997;33:215-219.
10. Thomas N. Piroxicam-associated gastric ulceration in a dog. Compend Cont Educ Pract Vet 1987;201:1004-1031.
11. Ewing G. Indomethacin-associated gastrointestinal hemorrhage in a dog. J Am Vet Med Assoc 1972;161:1665-1668.
12. Vonderhaar M, Salisbury S. Gastroduodenal ulceration associated with flunixin meglumine administration in three dogs. J Am Vet Med Assoc 1993;203:92-95.
13. Godshalk C, Roush J, Fingland R, et al. Gastric perforation associated with administration of ibuprofen in a dog. J Am Vet Med Assoc 1992;201:1734-1736.
14. Pfizer Animal Health, Inc. Carprofen Package Insert. Exton, PA: Pfizer Animal Health, Inc; 2000:1.
15. Davidson G. Etodolac. Compend Contin Educ Pract Vet 1999;21:494-495.
16. Wallace MS, Zawie DA, Garvey MS. Gastric ulceration in the dog secondary to the use of non-steroidal antiinflammatory drugs. J Am Anim Hosp Assoc 1990;26:467-472.
17. Jones J, Bailey RT Jr. Misoprostol: A prostaglandin E1 analog with antisecretory and cytoprotective properties. DICP 1989;23:276-282.
18. Porro GB, Lazzaroni M, Petrillo M. Double-blind, double-dummy endoscopie comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients. Am J Gastroenterol 1997;92:663-667.
19. Graham D, Agrawal N, Roth S. Prevention of NSAID-induced gastric ulcer with misoprostol; multicentre, double-blind, placebo-controlled trial. Lancet 1988;2:1277-1280.
20. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDS. Ann Intern Med 1993;119:258-261.
21. Lanza F. A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Dig Dis Sci 1986;31:131-136S.
22. Lanza F, Aspinall R, Swabb E, et al. Double-blind, placebo controlled endoscopie comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology 1988;95:289-294.
23. Lanza F, Kochman R, Geis G, et al. A double-blind, placebo-controlled, 6 day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits. Am J Gastroenterol 1991;86:1743-1748.
24. Agrawal N, Saffouri B, Kruss D, et al. Healing of benign gastric ulcer: A placebo-controlled comparison of two dosage regimens of misoprostol, a synthetic prostaglandin E1. Dig Dis Sci 1985;30:164-170S.
25. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. Ann Intern Med 1991;115:195-200.
26. Silverstein F, Kimmey M, Saunders D, et al. Gastric protection by misoprostol against 1300 mg of aspirin. Dig Dis Sci 1986;31:137-141S.
27. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-249.
28. Jiranek G, Kinney M, Saunders D, et al. Misoprostol reduces gastroduodenal injury from one week of aspirin: An endoscopic study. Gastroenterology 1989;96:656-661.
29. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of non-steroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens. Ann Intern Med 1995;123:344-350.
30. Santillan R, Garcia G, Garcia E. Prevention of gastroduodenal injury induced by NSAIDs with low-dose misoprostol. Proc West Pharmacol Soc 1999;42:33-34.
31. Bowersox TS, Lipowitz AJ, Hardy RM, et al. The use of a synthetic prostaglandin E1 analog as a gastric protectant against aspirin-induced hemorrhage in the dog. J Am Anim Hosp Assoc 1996;32:401-407.
32. Johnston SA, Leib MS, Forrester SD, et al. The effect of misoprostol on aspirin-induced gastroduodenal lesions in dogs. J Vet Intern Med 1995;9:32-38.
33. Murtaugh RJ, Matz ME, Labato MA, et al. Use of synthetic prostaglandin E1 (misoprostol) for the prevention of aspirin-induced gastroduodenal ulceration in arthritic dogs. J Am Vet Med Assoc 1993;202:251-256.
34. Wilson D, Quadros E, Rajapaksa T, et al. Effects of misoprostol on gastric acid and mucus secretion in man. Dig Dis Sci 1986;31:126-129S.
35. Sellers L, Carroll N, Allen A. Misoprostol-induced increases in adherent gastric mucus thickness and luminal mucus output. Dig Dis Sci 1986;31:91-95S.
36. Allen A, Carroll N. Adherent and soluble mucus in the stomach and duodenum. Dig Dis Sci 1985;30:55-62S.
37. Smedfors B, Johansson C. Stimulation of duodenal bicarbonate secretion by misoprostol. Dig Dis Sci 1986;31:96-100S.
38. Isenberg J, Hogan D, Selling J, et al. Duodenal bicarbonate secretion in humans. Dig Dis Sci 1986;31:130S.
39. Henagan JM, Schmidt KL, Miller TA. Prostaglandin prevents aspirin injury in the canine stomach under in vivo but not in vitro conditions. Gastroenterology 1989;97:649-659.
40. Gana T, MacPherson B, Ng D, et al. Ionic fluxes induced by topical misoprostol in canine gastric mucosa. Can J Physiol Pharmacol 1989;67:353-358.
41. Bolton J, Cohen M. Effect of 16,16-dimethyl prostaglandin E2 on the gastric mucosal barrier. Gut 1979;20:513-517.
42. Bauer R. Misoprostol preclinical pharmacology. Dig Dis Sci 1985;30:118S-125S.
43. Bauer R, Bianchi R, Casler J, et al. Comparative mucosal protective properties of misoprostol, cimetidine and sucralfate. Dig Dis Sci 1986;31:81-85S.
44. Gana T, MacPherson B, Koo J. The dose-response of canine focal gastric mucosal blood flow to misoprostol. Scand J Gastroenterol 1989;24:423-429.
45. Leung F, Miller J, Guth P. Dissociated effects of misoprostol on gastric acid secretion and mucosal blood flow. Dig Dis Sci 1986;31: 86-90S.
46. Goodlad R, Madgwick A, Moffatt M, et al. Prostaglandins and the dog stomach: Effects of misoprostol on the proportion of mucosa to muscle and on the proportion of different epithelial cell types. Digestion 1990;45:212-216.
47. Goodlad R, Madgwick A, Moffatt M, et al. Effects of misoprostol on cell migration and transit in the dog stomach. Gastroenterology 1990;98:90-95.
48. Goodlad R, Madgwick A, Moffatt M, et al. The effects of prostaglandin analogue, misoprostol, on cell proliferation and cell migration in the canine stomach. Digestion 1990;46:182-187.
49. Goodlad R, Madgwick A, Moffatt M, et al. Prostaglandins and the dog stomach: effects of misoprostol on the proportion of mucosa to muscle and on the proportion of different epithelial cell types. Digestion 1990;45:212-216.
50. Goodlad R, Ghatei M, Bloom S, et al. Plasma and tissue hormones in the dog after administration of the prostaglandin analogue, misoprostol. Digestion 1992;53:1-7.
51. Gabriel S, Campion M, O'Fallon W. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994;37:333-341.
52. Reimer M, Johnston S, Leib M, et al. The gastroduodenal effects of buffered aspirin, carprofen, and etodolac in healthy dogs. J Vet Intern Med 1999;13:474-477.
53. Mulleners W, Whitmarsh T, Steiner T. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia 1998;18:52-56.
54. Leenen F, Wilson T, Bolli P, et al. Patterns of compliance with once versus twice daily anti-hypertensive drug therapy in primary care: A randomized clinical trial using electronic monitoring. Can J Cardiol 1997;13:914-920.
55. Brooks P. NSAID - Differences and similarities. N Engl J Med 1991;324:1716-1725.
56. Forsyth S, Guilford W, Lawoko C. Endoscopic evaluation of the gastroduodenal mucosa following non-steroidal anti-inflammatory drug administration in the dog. N Z Vet J 1996;44:179-181.
57. Taylor L, Crawford L. Aspirin-induced gastrointestinal lesions in the dog. J Am Vet Med Assoc 1968;152:617-619.
58. Roth L, Leib M, Davenport D, et al. Comparisons between endoscopic and histologic evaluation of the gastrointestinal tract in dogs and cats: 75 cases (1984-87). J Am Vet Med Assoc 1990;196:635-638.
59. Gugler R. Current diagnosis and selection of patients for treatment of peptic ulcer disease. Dig Dis Sci 1985;30:30-35S.
60. Forsyth S, Guilford W, Haslett S, et al. Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs. J Small Anim Pract 1998;39:421-424.
61. Lanza F, Royer G, Nelson R. Endoscopie evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on the gastric and duodenal mucosa. N Engl J Med 1980;303:136-138.
62. Lanza F, Nelson R, Greenberg B. Effects of fenbufen, indomethacin, naproxen and placebo on the gastric mucosa of normal volunteers. Am J Med 1983;75:75-79.
63. Robinson M, Griffin J, Bowers J. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989;34:424-428.
64. Davis L. Clinical pharmacology of salicylates. J Am Vet Med Assoc 1980;176:65-66.
65. Plumb DC. Veterinary Drug Handbook, 3rd ed. Ames, IA: Iowa State University Press; 1999:66-70.
66. Davis L, Westfall B. Biotransformation and pharmacokinetics of salicylate in newborn animals. Am J Vet Res 1973;34:1105-1108.
67. Lipowitz A, Boulay J, Klausner J. Serum salicylate concentrations and endoscopic evaluation of the gastric mucosa in dogs after oral administration of aspirin-containing products. Am J Vet Res 1986;47:1586-1589.
68. Cook CS, Schoenhard GL, Karim A. Effects of salicylic acid on the plasma protein binding and pharmacokinetics of misoprostol acid. J Pharm Sci 1994;83:883-886.
69. Graham D, Smith J, Spjut H, et al. Gastric adaptation studies in humans using continuous aspirin administration. Gastroenterology 1988;90:327-333.
70. Hurley J, Crandall L. The effects of salicylates upon the stomach of dogs. Gastroenterology 1964;46:36-43.
71. Johnston S, Leib M, Marini M, et al. Endoscopic evaluation of the stomach and duodenum after administration of piroxicam to dogs. J Vet Intern Med 1997;11:117 (abstract).
72. Waki S, Kinoshita Y, Fukui H, et al. Intragastric distribution of nonsteroidal anti-inflammatory drug-related ulcers in patients without collagen disease. J Clin Gastroenterol 1997;25:592-594.
73. Dow S, Rosychuk R, McChesney A, et al. Effects of flunixin and flunixin plus prednisone on the gastrointestinal tract of dogs. Am J Vet Res 1990;51:1131-1138.
74. Herting R, Clay G. Overview of clinical safety with misoprostol. Dig Dis Sci 1985;30:185-193S.